Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline
Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.
You may also be interested in...
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Otsuka's novel ADHD therapy moves closer to a potential filing after meeting its endpoint in two Phase III trials, validating a past acquisition and further bolstering the Japanese firm's CNS prospects.
Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.